Generic OTC Lamisil approved
This article was originally published in The Tan Sheet
Executive Summary
FDA on July 2 approves Taro Pharmaceutical U.S.A's application for a generic version of Novartis' OTC athlete's foot cream Lamisil AT (terbinafine hydrochloride, 1 percent). Taro's product will be the first generic Lamisil cream on the market, according to FDA. The firm was granted tentative approval in March 2006 (1"The Tan Sheet" March, 27, 2006, p. 11). Novartis recently introduced a gel form, Lamisil AT Gel Advanced, which "cures most athlete's foot with 1/2 the applications of any other product," according to the product Web site. FDA also approved the first generic versions of Rx Lamisil tablets as the remaining patent or exclusivity for the drug expired June 30...
You may also be interested in...
Taro Granted Tentative Approval For First Lamisil Cream Equivalent
Taro Pharmaceuticals has received what appears to be the first tentative approval in the U.S. for a generic version of Novartis' OTC antifungal cream Lamisil, the Israeli firm announced March 23
European SEAC Opinion Unchanged: Microplastics Must Be Out Of All Cosmetics Within Six Years
The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.
QUOTED. 2 March 2021. Michael Coyle.
Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: